Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Works matching IS 02508095 AND DT 2010 AND VI 31 AND IP 5
Results: 15
1
2
Suppressor of cytokine signaling-1 ameliorates expression of MCP-1 in diabetic nephropathy.
- Published in:
- 2010
- By:
- Publication type:
- journal article
3
C-peptide as a therapeutic tool in diabetic nephropathy.
- Published in:
- 2010
- By:
- Publication type:
- journal article
4
Hepatitis E Virus Infection: A General Review with a Focus on Hemodialysis and Kidney Transplant Patients.
- Published in:
- American Journal of Nephrology, 2010, v. 31, n. 5, p. 398, doi. 10.1159/000294505
- By:
- Publication type:
- Article
5
Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review.
- Published in:
- 2010
- By:
- Publication type:
- journal article
6
Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients.
- Published in:
- 2010
- By:
- Publication type:
- journal article
7
Variability of creatinine measurements in clinical laboratories: results from the CRIC study.
- Published in:
- 2010
- By:
- Publication type:
- journal article
8
Indoxyl Sulfate Upregulates Expression of ICAM-1 and MCP-1 by Oxidative Stress-Induced NF-κB Activation.
- Published in:
- American Journal of Nephrology, 2010, v. 31, n. 5, p. 435, doi. 10.1159/000299798
- By:
- Publication type:
- Article
9
Hydrogen sulfide regulates homocysteine-mediated glomerulosclerosis.
- Published in:
- 2010
- By:
- Publication type:
- journal article
10
Title Page. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?
- Published in:
- American Journal of Nephrology, 2010, v. 31, n. 5, p. 457, doi. 10.1159/000313548
- Publication type:
- Article
11
Debate: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?
- Published in:
- American Journal of Nephrology, 2010, v. 31, n. 5, p. 458, doi. 10.1159/000292501
- By:
- Publication type:
- Article
12
Debate: CON Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?
- Published in:
- American Journal of Nephrology, 2010, v. 31, n. 5, p. 462, doi. 10.1159/000313553
- By:
- Publication type:
- Article
13
Rebuttal: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?
- Published in:
- American Journal of Nephrology, 2010, v. 31, n. 5, p. 466, doi. 10.1159/000313562
- By:
- Publication type:
- Article
14
Rebuttal: CON Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?
- Published in:
- American Journal of Nephrology, 2010, v. 31, n. 5, p. 468, doi. 10.1159/000313583
- By:
- Publication type:
- Article
15
Editorial Perspective. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial?
- Published in:
- American Journal of Nephrology, 2010, v. 31, n. 5, p. 469, doi. 10.1159/000292500
- By:
- Publication type:
- Article